These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37269669)

  • 21. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
    To KKW; Xing E; Larue RC; Li PK
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.
    French CA; Ramirez CL; Kolmakova J; Hickman TT; Cameron MJ; Thyne ME; Kutok JL; Toretsky JA; Tadavarthy AK; Kees UR; Fletcher JA; Aster JC
    Oncogene; 2008 Apr; 27(15):2237-42. PubMed ID: 17934517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
    Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
    Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
    [No Abstract]   [Full Text] [Related]  

  • 24. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
    Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
    Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
    Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma.
    Markman RL; Webber LP; Nascimento Filho CHV; Reis LA; Vargas PA; Lopes MA; Zanella V; Martins MD; Squarize CH; Castilho RM
    Cell Oncol (Dordr); 2019 Apr; 42(2):143-155. PubMed ID: 30539410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
    Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
    J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.
    Gallagher SJ; Mijatov B; Gunatilake D; Tiffen JC; Gowrishankar K; Jin L; Pupo GM; Cullinane C; Prinjha RK; Smithers N; McArthur GA; Rizos H; Hersey P
    J Invest Dermatol; 2014 Nov; 134(11):2795-2805. PubMed ID: 24906137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging roles of and therapeutic strategies targeting BRD4 in cancer.
    White ME; Fenger JM; Carson WE
    Cell Immunol; 2019 Mar; 337():48-53. PubMed ID: 30832981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
    Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
    Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
    Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells.
    Zhang K; Gao L; Wang J; Chu X; Zhang Z; Zhang Y; Fang F; Tao Y; Li X; Tian Y; Li Z; Sang X; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Hu S
    Pathol Oncol Res; 2022; 28():1610447. PubMed ID: 35832114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.
    Picaud S; Da Costa D; Thanasopoulou A; Filippakopoulos P; Fish PV; Philpott M; Fedorov O; Brennan P; Bunnage ME; Owen DR; Bradner JE; Taniere P; O'Sullivan B; Müller S; Schwaller J; Stankovic T; Knapp S
    Cancer Res; 2013 Jun; 73(11):3336-46. PubMed ID: 23576556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
    Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
    ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.
    Segura MF; Fontanals-Cirera B; Gaziel-Sovran A; Guijarro MV; Hanniford D; Zhang G; González-Gomez P; Morante M; Jubierre L; Zhang W; Darvishian F; Ohlmeyer M; Osman I; Zhou MM; Hernando E
    Cancer Res; 2013 Oct; 73(20):6264-76. PubMed ID: 23950209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma.
    Kfoury N; Qi Z; Prager BC; Wilkinson MN; Broestl L; Berrett KC; Moudgil A; Sankararaman S; Chen X; Gertz J; Rich JN; Mitra RD; Rubin JB
    Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33850013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
    Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
    EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts.
    Klein K; Kabala PA; Grabiec AM; Gay RE; Kolling C; Lin LL; Gay S; Tak PP; Prinjha RK; Ospelt C; Reedquist KA
    Ann Rheum Dis; 2016 Feb; 75(2):422-9. PubMed ID: 25467295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.
    Lambert JP; Picaud S; Fujisawa T; Hou H; Savitsky P; Uusküla-Reimand L; Gupta GD; Abdouni H; Lin ZY; Tucholska M; Knight JDR; Gonzalez-Badillo B; St-Denis N; Newman JA; Stucki M; Pelletier L; Bandeira N; Wilson MD; Filippakopoulos P; Gingras AC
    Mol Cell; 2019 Feb; 73(3):621-638.e17. PubMed ID: 30554943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases.
    Kulikowski E; Rakai BD; Wong NCW
    Med Res Rev; 2021 Jan; 41(1):223-245. PubMed ID: 32926459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.